Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 3, 2001, Pages 1126-1133

  Jakubowicz, Daniela J ^a,b   Seppälä, Markku ^c   Jakubowicz, Salomon ^b   Rodriguez Armas, Otto ^b   Rivas Santiago, Asdrubal ^b   Koistinen, Hannu ^c   Koistinen, Riitta ^c   Nestler, John E ^d  

^a Hospital de Clinicas Caracas   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c UNIVERSITY OF HELSINKI   (Finland)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; INSULIN; METFORMIN; PLACEBO; PLACENTA PROTEIN 14; SOMATOMEDIN BINDING PROTEIN 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; FOLLICULAR PHASE; HUMAN; HYPERINSULINEMIA; LUTEAL PHASE; NIDATION; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; UTERUS BLOOD FLOW;

EID: 0035044332     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.3.1126     Document Type: Article

References (68)

1. Polycystic ovary syndrome
2. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin
3. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
4. Hypersecretion of luteinising hormone, infertility, and miscarriage
5. Recurrent early miscarriage and polycystic ovaries
6. Hypersecretion of iuteinizing hormone and ovarian steroids in women with recurrent early miscarriage
7. Recurrent miscarriage. II. Clinical associations, causes, and management
8. Insulin resistance in nonobese patients with polycystic ovarian disease
9. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
10. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome
11. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus
12. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
13. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
14. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome
15. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
16. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome
17. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
18. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
19. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
20. Ovulatory and metabolic effects of d-chiro-inositol in the polycystlc ovary syndrome
21. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome
22. Quantitative assessment of subendometrial blood flow by three-dimensional-ultrasound is an important predictive factor of implantation in an in-vitro fertilization programme
23. Vaginal color Doppler assessment of uterine artery impedance correlates with immunohistochemical markers of endometrial receptivity required for the implantation of an embryo
24. Endometrial thickness, morphology, vascular penetration and velocimetry in predicting implantation in an in vitro fertilization program
25. Transvaginal color Doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary disease
26. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: Correlation with serum hormone concentrations
27. Structural studies, localization in tissue and clinical aspects of human endometrial proteins
28. Secretory endometrium synthesizes placental protein 14
29. Identification by hybridization histochemistry of human endometrial cells expressing mRNAs encoding a uterine β-lactoglobulin homologue and insulin-like growth factor-binding protein-1
30. Identification of placental protein 14 as an immunosuppressive factor in human reproduction
31. Suppression by human placental protein 14 of natural killer cell activity
32. The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology
33. Habitual abortion is accompanied by low serum levels of placental protein 14 in the luteal phase of the fertile cycle
34. Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface
35. 1 integrin by means of its Arg-Gly-Asp sequence
36. Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease
37. Polycystic ovarian disease: US features in 104 patients
38. Luteal phase defect: Comparison between Doppler velocimetry, histological and hormonal markers
39. Effect of marathon run on serum IGF-I and IGF-binding protein 1 and 3 levels
40. Glycodelin from seminal plasma is a differentially glycosylated form of contraceptive glycodelin-A
41. Calculation of ffee and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature
42. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens
43. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
44. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
45. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
46. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus
47. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
48. Serum levels of placental protein 14 reflect ovulation in nonconceptional menstrual cycles
49. Distribution of placental protein 14 in tissues and body fluids during pregnancy
50. Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities
51. A role for glycoconjugates in human development: The human feto-embryonic defence system hypothesis
52. The somatomedin-binding protein isolated from a human hepatoma cell line is identical to the human amniotic fluid somatomedin-binding protein
53. Synthesis of placental protein 12 by human endometrium
54. Human granulosa cells synthesize low molecular weight insulin-like growth factor-binding protein
55. Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin
56. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells
57. The insulin-related ovarian regulatory system in health and disease
58. Differential regulation of insulin-like growth factor binding protein secretion from human decidual cells by IGF-I, insulin, and relaxin
59. Progesterone-associated endometrial protein: A constitutive marker of human erythroid precursors
60. Expression of glycodelin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium
61. Expression of glycodelin in human breast and breast cancer
62. Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties
63. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function
64. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: Prospective study in 50 women
65. The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries
66. Aromatase activity in human granulosa cells during follicular development and the modulation of follicle-stimulating hormone and insulin
67. Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I
68. Insulin mediators are the signal transduction system responsible for insulin's actions on human placental steroidogenesis